Zelluna plans to submit its Clinical Trial Application (CTA) in late 2025, with first patient data expected mid-2026.

A novel cell therapy

The paper describes ZI-MA4-1, a novel cell therapy that combines two cancer-fighting mechanisms: the precision solid tumor targeting of T cell receptors (TCRs) with the potent and broad cancer killing ability of Natural Killer (NK) cells. ZI-MA4-1 targets MAGE-A4, a protein found in many solid cancers including lung, ovarian, head and neck, and sarcomas.

Since ZI-MA4-1 is manufactured in advance and stored frozen, it can be given to patients on demand (off-the-shelf), enabling multiple doses for sustaining a tumour response and broad patient access.

“Validates our approach”

“This publication validates our approach,” says Luise Weigand, Zelluna’s Chief Scientific Officer. “It is also a testament to the dedication and innovation of our talented team. With our preclinical data completed, manufacturing process locked, and clinical material ready, we are well-positioned to start clinical trials in 2026.”